Healthcare physicians rely on tests which are able to identify the DNA of the
bacteria responsible for sexually transmitted diseases (e.g., HIV, Chlamydia,
gonorrhoea) and other infectious diseases such as MRSA. This is the largest
sector of the genetic diagnostics market today and is concentrated in central
laboratories which batch and test high volumes of samples. Osmetech's aim
through its OPTI GENE instrument is to improve the turn around time of testing
in this area sufficiently to justify a shift in testing away from the central
laboratory to near point of care. An easy to perform test which can provide a
result within 45 minutes, whilst the patient is still at the hospital or clinic
presents a significant opportunity to control the spread of disease both in the
hospital and in the general population. These attributes are also expected to
be useful for the effective diagnosis for emerging contagious diseases such as
Bird Flu.
I wonder how the last paragraph above relates to the news from today shown below, (are these the type of tests OMH could be looking at?).
Osmetech stock quotes
Osmetech stock charts
Follow this thread
